Renaissance Technologies
EDIT icon

Renaissance Technologies’s Editas Medicine EDIT Stock Holding History

Renaissance Technologies’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8M Sell
2,468,919
-1,503,241
-38% -$4.39M 0.01% 1180
2026
Q1 		$9.81M Buy
3,972,160
+932,382
+31% +$1.97M 0.02% 981
2025
Q4 		$6.23M Buy
3,039,778
+1,762,378
+138% +$5.09M 0.01% 1181
2025
Q3 		$4.43M Buy
1,277,400
+389,000
+44% +$1.09M 0.01% 1574
2025
Q2 		$1.95M Sell
888,400
-144,565
-14% -$237K ﹤0.01% 2128
2025
Q1 		$1.2M Sell
1,032,965
-418,084
-29% -$615K ﹤0.01% 2296
2024
Q4 		$1.84M Buy
+1,451,049
New +$3.7M ﹤0.01% 2108
2024
Q3 		– Sell
-98,429
Closed -$460K – 3614
2024
Q2 		$460K Sell
98,429
-799,989
-89% -$4.51M ﹤0.01% 2731
2024
Q1 		$6.67M Buy
898,418
+391,018
+77% +$3.25M 0.01% 1232
2023
Q4 		$5.14M Buy
507,400
+442,900
+687% +$3.89M 0.01% 1327
2023
Q3 		$503K Sell
64,500
-91,800
-59% -$787K ﹤0.01% 2701
2023
Q2 		$1.29M Buy
+156,300
New +$1.36M ﹤0.01% 2309
2022
Q2 		– Sell
-903,400
Closed -$17.2M – 4302
2022
Q1 		$17.2M Buy
903,400
+675,300
+296% +$12.6M 0.02% 839
2021
Q4 		$6.06M Buy
+228,100
New +$7.85M 0.01% 1398
2021
Q3 		– Sell
-140,000
Closed -$7.93M – 3551
2021
Q2 		$7.93M Sell
140,000
-315,927
-69% -$11.7M 0.01% 1335
2021
Q1 		$19.1M Buy
+455,927
New +$26M 0.02% 797
2020
Q4 		– Sell
-106,100
Closed -$2.98M – 3451
2020
Q3 		$2.98M Sell
106,100
-94,000
-47% -$3.06M ﹤0.01% 1880
2020
Q2 		$5.92M Sell
200,100
-100,800
-33% -$2.63M 0.01% 1533
2020
Q1 		$5.97M Buy
300,900
+218,800
+267% +$5.52M 0.01% 1464
2019
Q4 		$2.43M Buy
+82,100
New +$2.05M ﹤0.01% 2227
2019
Q2 		– Sell
-371,400
Closed -$9.08M – 3589
2019
Q1 		$9.08M Buy
371,400
+99,400
+37% +$2.25M 0.01% 1435
2018
Q4 		$6.19M Sell
272,000
-28,100
-9% -$765K 0.01% 1586
2018
Q3 		$9.55M Buy
+300,100
New +$9.7M 0.01% 1390
2016
Q4 		– Sell
-128,400
Closed -$1.73M – 3291
2016
Q3 		$1.73M Buy
128,400
+106,096
+476% +$2.17M ﹤0.01% 2278
2016
Q2 		$544K Buy
+22,304
New +$752K ﹤0.01% 2766

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Renaissance Technologies's EDIT Position: Q2 2026 in Review

Renaissance Technologies reduced its Editas Medicine (EDIT) stake by 38% in Q2 2026, selling an estimated $4.39M and leaving 2,468,919 shares worth $8M. The position accounts for 0.01% of the portfolio, ranked #1180.

Renaissance Technologies first reported a position in EDIT in Q2 2016 and has held it in 25 quarters since. The position peaked at $19.1M in Q1 2021. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Renaissance Technologies held 2,468,919 shares of Editas Medicine worth $8M as of Q2 2026.
  • Renaissance Technologies sold 1,503,241 Editas Medicine shares in Q2 2026, an estimated $4.39M.
  • Editas Medicine made up 0.01% of Renaissance Technologies's portfolio in Q2 2026, its #1180 holding.
  • Renaissance Technologies first reported a position in Editas Medicine in Q2 2016 and has held it in 25 quarters since.
  • Renaissance Technologies's Editas Medicine position peaked at $19.1M in Q1 2021.
  • 214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.